Jasper Therapeutics, Inc.
JSPR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $56 | $52 | $35 | $25 |
| G&A Expenses | $20 | $17 | $17 | $11 |
| SG&A Expenses | $20 | $17 | $17 | $11 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $76 | $69 | $51 | $37 |
| Operating Income | -$76 | -$69 | -$51 | -$37 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $5 | $4 | $14 | $6 |
| Pre-Tax Income | -$71 | -$64 | -$38 | -$31 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$71 | -$64 | -$38 | -$31 |
| % Margin | – | – | – | – |
| EPS | -4.89 | -6.18 | -10.33 | -26.89 |
| % Growth | 20.9% | 40.2% | 61.6% | – |
| EPS Diluted | -4.89 | -6.18 | -10.33 | -26.89 |
| Weighted Avg Shares Out | 15 | 10 | 4 | 1 |
| Weighted Avg Shares Out Dil | 15 | 10 | 4 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $5 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $0 |
| EBITDA | -$75 | -$68 | -$50 | -$36 |
| % Margin | – | – | – | – |